Joe Pitts

Technology has the potential to transform health care as well, and in doing so address many of the challenges that we currently face.

As part of our committee's 21st Century Cures Initiative, we are examining the discovery, development, and delivery process to speed new treatments and cures to patients.

If the June 2014 Rand report is true, we have been subsidizing systems that block information instead of allowing for information transfers, which was never the intent of the statute.

Given the Administration's false promises when it comes to Affordable Care Act implementation, CMS' hope to have a fully automated process up and running later this summer deserves to be treated with skepticism.

It is absolutely stunning that this Administration, nearly a year after launch of the exchanges and with $1 trillion on the line, has yet to build a functioning eligibility system.

According to the reports, between October 1st and December 31st, 2013, OIG identified 2.9 million inconsistencies between applicants' information and data received through the Data Hub or from other data sources.

The subcommittee will come to order.

I really urged that we make sure that we are out there in the community so that anyone who has lung cancer has an opportunity to participate in this research and perhaps have a more effective therapy.

Today's hearing provides us with an opportunity to examine perhaps one of the most important aspects of the 21st Century Cures Initiative.

This expensive and antiquated clinical trials model is simply not acceptable in the 21st century.

Part of the work of our 21st Century Cures Initiative is to identify existing roadblocks to speeding treatments and cures to patients.

Again, Mr. Speaker, H.R. 4080 is another very important and bipartisan bill, and I urge all of the Members to support it. I yield back the balance of my time. The SPEAKER pro tempore (Mr. Jolly). The question is on the motion offered by…

I am very pleased to support this very important bipartisan legislation. I urge all Members to do so, and I yield back the balance of my time.

At this time I yield 1 minute to the distinguished gentleman from Florida (Mr. Bilirakis), a valued member of the Health Subcommittee.

At this time, I yield 5 minutes to the gentleman from New Jersey, Congressman Chris Smith, the distinguished prime sponsor of the legislation, who has really provided the leadership on this issue.

I think it is unacceptable that the administration continues to give Americans the false impression that this promise is somehow true.

Yet as we now know, this promise was simply not true.

As a result, many plans are turning to narrower provider networks and skimpier prescription drug coverage to keep premiums and deductibles in check.

The President's health care law was sold to the American people with a number of promises: If you like your plan, you will be able to keep it; if you like your doctor, you will be able to continue seeing him or her.

Yet, as we now know, this promise was simply not true.

I hate to cut this off, but this has been the best interaction we have had with members and witnesses.

I urge my colleagues to take swift action and aggressive action because we do not have a moment to waste.

We have a huge opportunity to incentivize them.

The cost of developing a drug has doubled, as has the number of clinical trials necessary to file a new drug application.

To help close this innovation gap, as part of 21st Century Cures Initiative, we must take a fresh look at the challenges facing innovative companies and make certain the right incentives are in place so America is home to the next…